Skip to main navigation
Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Email Alerts

Required fields denoted by an asterisk ().
Alert type

Investor Tools

  • Email Alerts
  • Investor FAQs
  • RSS Feeds
  • Contact Us
About

We are biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. We have developed two unique approaches – a TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and an ImmunoPhage™ platform that leverages bacteriophage to fully engage the immune system. Using our TMAb platform, we developed SNS-101, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, we are developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. This platform is designed to enable efficient, scalable and cost-effective manufacturing to support our clinical programs. SNS-401-NG is a next generation ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma.

Contact
Headquarters
451 D Street, Suite 710
Boston, MA 02210
Phone No
phone-icon

+1.240.243.8000

 

Maryland Location
1405 Research Blvd, Suite 125
Rockville, MD 20850
Email
email-icon

info@senseibio.com

 

© 2022 Sensei Biotherapeutics, Inc. All Rights Reserved.

Legal

  • Privacy Policy

Social Links

Go to Top